Charco Neurotech
Charco Neurotech is a Cambridge-based medical device company developing non-invasive wearable neuromodulation devices (CUE1, CUE1+) for people with Parkinson's disease, sold direct-to-consumer in the UK with recurring consumable revenue and pursuing international regulatory approvals.
- Company typePrivate
- Founded2013
- HeadquartersCambridge, United Kingdom
- Headcount11–50
- GTM typeB2C
- OfferingHardware or Manufacturing
What Charco Neurotech does
Charco Neurotech is a Cambridge, UK-based medical device company founded in 2013 that develops non-invasive wearable neuromodulation technology for people with Parkinson's disease. Its flagship products, the CUE1 and CUE1+, are wearable devices worn on the sternum that deliver focused vibrotactile stimulation and pulsed cueing to motor neurons, with the intended effect of reducing bradykinesia and rigidity. The technology is supported by a randomized controlled trial demonstrating a 15.6-point MDS-UPDRS Part III motor improvement in active participants versus 4.5 points in sham controls (p=0.002), and the company holds 2 granted patents with 1 pending application, plus ISO 13485:2016 certification.
The company operates a direct-to-consumer e-commerce model in the United Kingdom, where sales are currently temporarily paused, and generates recurring revenue from proprietary adhesive patches sold either as one-time purchases or via subscription. Charco has built a user base of over 3,000 individuals and has established research and advocacy partnerships with Parkinson's UK, the European Parkinson's Disease Association, Imperial College London, University College London, Queen Mary University of London, and NHS trusts. The CUE companion app provides symptom-tracking functionality that produces longitudinal usage data.
Charco is actively pursuing regulatory clearances across the US (FDA), Australia (TGA), South Korea, Europe (CE marking), and Saudi Arabia to expand beyond its UK-only commercial footprint. The company maintains operations in Cambridge with a presence in South Korea and is led by founder and Chief Medical Officer Floyd Pierres alongside a full executive team covering data, operations, science, commercial, and clinical functions.
Charco Neurotech firmographics
Firmographics- Name
- Charco Neurotech
- Legal name
- Charco Neurotech Ltd
- Website
- https://charconeurotech.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Charco Neurotech is a Cambridge-based medical device company developing non-invasive wearable neuromodulation devices (CUE1, CUE1+) for people with Parkinson's disease, sold direct-to-consumer in the UK with recurring consumable revenue and pursuing international regulatory approvals.
- Ownership category
- akta.pro rank
Charco Neurotech industry classification
Industry- Product category
- Wearable Neuromodulation Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices) (HLAHAMAG)
- akta.pro secondary industry
- Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices) (CRACAQAL)
Keywords
Where Charco Neurotech is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
Charco Neurotech business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations
Revenue model
- CUE1+ Device Sales: One-time purchase of the CUE1+ wearable neuromodulation device. The device includes charging dock, USB cable, and 3-month supply of adhesive patches. Currently available for sale in the UK only, with temporary pause noted for regulatory updates.
- Consumable Adhesives: Recurring revenue from replacement adhesive patches. Body Adhesives Pack (£15 ex VAT) contains 6 body adhesives and 1 device adhesive, lasts approximately 3 months. Device Adhesives Pack (£5 ex VAT) contains 3 device adhesives. Subscription option available for body adhesives every 3 months.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Pay-as-you-go | Body Adhesives Pack - £15.00 ex VAT |
| Unit Pricing | Pay-as-you-go | Device Adhesives Pack - £5.00 ex VAT |
| One time/ perpetual license | Pay-as-you-go | CUE1+ Device - Price not publicly disclosed |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels8 records
Charco Neurotech product offering
Product offeringCore offering
Charco Neurotech designs, manufactures, and sells the CUE1/CUE1+, a non-invasive, wearable, sternum-mounted medical device that delivers focused vibrotactile stimulation and pulsed cueing to alleviate motor symptoms of Parkinson's disease (bradykinesia, rigidity, stiffness, freezing of gait). The hardware is paired with the CUE mobile companion app and supported by recurring consumable adhesive packs, sold predominantly direct-to-consumer in the UK with healthcare-system procurement pathways under development.
Product overview
Charco Neurotech offers the CUE Device system, comprising the CUE1/CUE1+ core wearable medical device and the CUE companion mobile application. The CUE1/CUE1+ is a non-invasive wearable that uses vibrotactile stimulation and cueing to help people with Parkinson's improve movement and quality of life. The CUE app pairs with the device via Bluetooth to enable customization of stimulation settings, medication reminders, and symptom tracking. Consumable accessories include Body Adhesives Packs and Device Adhesives Packs for wearing and maintaining the device.
Differentiator
Problem solved
Functional benefit
Brands
- CUE1/CUE1+: Non-invasive wearable device for people with Parkinson's that delivers focused vibrotactile stimulation and cueing to alleviate motor symptoms including slowness, stiffness, rigidity, and freezing of gait.
Products and services
- CUE1/CUE1+ Wearable Neuromodulation Device A non-invasive, wearable medical device worn on the sternum that delivers pulsed cueing and high-frequency focused vibrotactile stimulation to alleviate motor symptoms of Parkinson's disease, including slowness, stiffness, rigidity, and freezing of gait. Sold direct-to-consumer in the UK, can be used standalone or paired with the CUE app.
- CUE Mobile App Bluetooth-connected iOS/Android app that lets users customize stimulation strength, pulse length, and rest length, set medication reminders, track mood and symptoms, access saved presets, and play symptom-tracking games.
- Body Adhesives Pack Pack of 6 body-side hypoallergenic medical-grade adhesive patches plus 1 device adhesive, lasting approximately 3 months. Body adhesives are applied to the skin for up to 14 days and use a hook-and-loop fastening system for attaching the CUE1+.
- Device Adhesives Pack Pack of 3 device-side hook-and-loop replacement adhesives for the CUE1/CUE1+, needed every few months because the scratchy surface picks up lint and fibres that reduce connection effectiveness.
Quantifiable outcome
- 15.6 point mean improvement in MDS-UPDRS Part III motor score (active) vs 4.5 (sham), p=0.002, in 50 participants over 12 weeks
- +4 more outcomes
Companies that use Charco Neurotech
Customer profileNamed customers7 records
Segments3 records
Ideal customer profiles3 records
Charco Neurotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Charco Neurotech partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- European Parkinson's Disease Association (Parkinson's Europe)coreStrategic partnership announced to expand reach of CUE1 device. Collaboration supports awareness and distribution through Parkinson's patient advocacy network across Europe.
- Queen Mary University of London (QMUL)coreResearch partnership for clinical trials. QMUL conducted landmark double-blind, sham-controlled, randomized study of CUE1+ at Centre for Preventive Neurology in collaboration with Barts Health NHS Trust and Homerton Healthcare NHS Foundation Trust. Results pre-published in MedRxiv (2025).
- Barts Health NHS TrustcoreNHS clinical trial site for double-blind RCT of CUE1+ device. 12-week trial with 50 participants comparing active device to sham control.
- Homerton Healthcare NHS Foundation TrustcoreNHS clinical trial site for double-blind RCT of CUE1+ device. 12-week trial with 50 participants comparing active device to sham control.
- LFH RegulatoryminorMedical device regulatory consultancy providing QMS implementation support for ISO 13485 certification process. Expert guidance made complex certification journey manageable.
- Imperial College LondonminorFounding institution where Charco Neurotech was founded. Historical partnership for research and development of CUE1 device.
- Cambridge University Hospitals NHS Foundation TrustminorConducted real-world feasibility study on CUE1 showing statistically significant improvements in motor scores and walking speed after four weeks of daily use in older adults with Parkinson's.
- Parkinson's UKcorePartnership supporting Parkinson's UK Walk for Parkinson series. CUE1+ featured in Parkinson's UK Tech Guide designed to help people with Parkinson's discover technology solutions.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
Charco Neurotech competitors and assessment
Company assessmentEmerging players
- Functional Neuromodulation: Functional Neuromodulation is a clinical-stage company developing DBS-based therapies targeting the fornix for Parkinson's disease and other neurodegenerative conditions. While it focuses on implantable DBS rather than wearables, it targets the same Parkinson's treatment paradigm and represents an adjacent emerging competitor in disease-modifying neuromodulation.
- Rune Labs: Rune Labs offers StrivePD, a software platform for Parkinson's patients and clinicians built on Apple Watch that integrates symptom tracking, medication adherence, and clinical decision support. It is comparable to Charco's CUE app as a digital Parkinson's companion, and the two could plausibly integrate or co-compete for clinician mindshare in Parkinson's digital therapeutics.
Broad incumbents
- LivaNova: LivaNova is a neuromodulation and cardiac surgery company with a deep brain stimulation portfolio for Parkinson's disease and other movement disorders. It competes with Charco for movement-disorder clinician relationships and represents an incumbent that could acquire or build a non-invasive wearable offering if the segment scales.
- Medtronic (Activa DBS): Medtronic's Activa deep brain stimulation system is one of the established implantable standards of care for advanced Parkinson's disease. As a non-invasive, lower-cost wearable, Charco sits at the opposite end of the Parkinson's treatment spectrum but competes for the same neurologist prescribing decisions and payer budgets.
- Boston Scientific (Vercise): Boston Scientific's Vercise deep brain stimulation platform is used to treat Parkinson's disease symptoms. As a large diversified neuromodulation player, Boston Scientific competes for the same clinicians and Parkinson's patient pool and has the resources to enter non-invasive wearable neuromodulation if the category proves commercially attractive.
- Abbott (Infinity DBS): Abbott's Infinity DBS system is an implantable deep brain stimulation therapy for Parkinson's disease and movement disorders. Abbott is a global medical device incumbent, and its DBS franchise represents the surgical alternative that Charco's non-invasive wearable is positioned against for newly diagnosed or earlier-stage patients.
Direct peers
- Gyenno Technologies: Gyenno Technologies is a Chinese medical technology company focused on Parkinson's and movement disorders, with products including smart stabilizing cutlery, gait-assist devices, and digital symptom-tracking software. It competes with Charco for the same Parkinson's patient population and overlaps on wearable assistive hardware and software-enabled symptom management.
- Steadiwear: Steadiwear develops the Steadi-Two glove, a battery-free wearable designed to stabilize hand tremor in people with essential tremor and Parkinson's disease. It targets the same Parkinson's/essential tremor patient population as Charco, using a non-invasive wearable approach to reduce motor symptoms during daily activities.
- Cala Health: Cala Health makes Cala Trio, a wrist-worn wearable neuromodulation device that delivers transcutaneous afferent patterned stimulation (TAPS) to reduce hand tremor, primarily for essential tremor and Parkinson's tremor. It is the closest direct analog to Charco's CUE1+ in modality (wearable, non-invasive, neuromodulation), therapeutic area (movement disorders), and business model (hardware plus clinician channel).
- Helius Medical Technologies: Helius Medical Technologies markets the Portable Neuromodulation Stimulator (PoNS), a non-invasive neurostimulation device used in neurorehabilitation for gait and balance deficits, including for patients with multiple sclerosis and mild-to-moderate traumatic brain injury. It is a direct peer in the non-invasive wearable neuromodulation category targeting movement and gait outcomes.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Charco Neurotech social profiles
Digital presenceCharco Neurotech compliance and trust
Trust signalCompliance1 record
Charco Neurotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Charco Neurotech leadership team
Management profileNumber of profiles
Profiles7 records
Charco Neurotech funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Charco Neurotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Charco Neurotech
What does Charco Neurotech do?
Charco Neurotech designs, manufactures, and sells the CUE1/CUE1+, a non-invasive, wearable, sternum-mounted medical device that delivers focused vibrotactile stimulation and pulsed cueing to alleviate motor symptoms of Parkinson's disease (bradykinesia, rigidity, stiffness, freezing of gait). The hardware is paired with the CUE mobile companion app and supported by recurring consumable adhesive packs, sold predominantly direct-to-consumer in the UK with healthcare-system procurement pathways under development.
Is Charco Neurotech a public or private company?
Charco Neurotech is a private company. It is classified as venture growth investor backed and is currently operating.
When was Charco Neurotech founded?
Charco Neurotech was founded in 2013. It employs 11 to 50 people.
Where is Charco Neurotech based?
Charco Neurotech is headquartered in Cambridge, United Kingdom, in the Europe region.
How does Charco Neurotech make money?
Two revenue lines are on record. CUE1+ Device Sales are the primary driver. The others are consumable Adhesives.
Who are Charco Neurotech's main competitors?
Emerging players on record are Functional Neuromodulation and Rune Labs. Broad incumbents are LivaNova, Medtronic (Activa DBS), Boston Scientific (Vercise) and Abbott (Infinity DBS). Direct peers are Gyenno Technologies, Steadiwear, Cala Health and Helius Medical Technologies.
Does Charco Neurotech have an API?
No public API is recorded for Charco Neurotech.
What industry is Charco Neurotech in?
Charco Neurotech's product category is Wearable Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAHAMAG, Rehabilitation Therapy Equipment (PT/OT Modalities, Exercise & Balance Devices), with a secondary code of CRACAQAL, Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices). Its NAICS code is 334510 and its SIC code is 3841.